Journal of Hepatology

The Journal of Hepatology, published by Elsevier on behalf of the European Association for the Study of the Liver (EASL), is the premier international peer-reviewed journal in the field of hepatology. With an outstanding 2026 Impact Factor of 40.100 and consistently ranked in the JCR Q1 quartile, it stands as the highest-impact journal dedicated exclusively to liver research and clinical practice. The journal’s scope encompasses the full spectrum of liver disease, including viral hepatitis, cirrhosis, hepatocellular carcinoma, metabolic liver disease, autoimmune and cholestatic disorders, liver transplantation, and biliary tract pathology. It publishes a wide array of article types, including original research articles, comprehensive reviews, concise rapid communications, editorials, and EASL Clinical Practice Guidelines, which set international standards for patient care. The target audience comprises hepatologists, gastroenterologists, infectious disease specialists, transplant surgeons, pathologists, and basic scientists investigating liver biology and pathophysiology. Notable features include a rigorous peer-review process, open access options for authors, and supplementary multimedia content such as video abstracts and podcasts. As the official journal of EASL, it serves as the leading voice in the specialty, providing essential, cutting-edge insights that drive clinical decision-making and shape the future of hepatology research worldwide. Its exceptional impact factor and top-tier quartile ranking underscore its unparalleled influence and prestige within the biomedical literature.